MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

Search

Zentalis Pharmaceuticals Inc

Closed

1.36 3.03

Overview

Share price change

24h

Current

Min

1.32

Max

1.42

Key metrics

By Trading Economics

Income

-807K

-48M

EPS

-0.67

Profit margin

-176.706

Employees

166

EBITDA

173K

-46M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+401.5% upside

Dividends

By Dow Jones

Next Earnings

8 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-2.2M

91M

Previous open

-1.67

Previous close

1.36

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Zentalis Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Sept 2024, 11:52 UTC

Major Market Movers

Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies

Peer Comparison

Price change

Zentalis Pharmaceuticals Inc Forecast

Price Target

By TipRanks

401.5% upside

12 Months Forecast

Average 6.67 USD  401.5%

High 10 USD

Low 4 USD

Based on 7 Wall Street analysts offering 12 month price targets forZentalis Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

4

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

1.23 / 1.45Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.